9702 Chinese patent medicines have been approved for production! How to avoid "collision"?

Not long ago, China's first "Chinese medicine law" was officially implemented, which presented a big gift to the Chinese medicine industry Analysts believe that many policy dividends it released will raise the research and development boom again, and have an impact on the trillion yuan Chinese medicine market In fact, the market of traditional Chinese medicine in 2016 was not satisfactory Taking the most representative Chinese patent medicine as an example, customs statistics show that in 2016, China's imports of Chinese patent medicine reached 321 million US dollars, a substantial increase of 10.57% year-on-year On the contrary, the annual export was not optimistic, with the export volume of 225 million US dollars, a decrease of 13.94% year-on-year The difference is obvious What's the problem? According to the statistics of CPM database of China Pharmaceutical Industry Information Center, it will take a long time to transform the international strong drugs At present, there are four varieties of Chinese patent medicines on the market in the world, which can be described as "few" There are 9702 Chinese patent medicines approved by the State Food and Drug Administration (CFDA), and the competition is fierce On the other hand, CFDA has approved the import of 49 Chinese patent medicines, 45 of which have not been approved to be made in China Domestic R & D gap still exists In terms of the distribution of dosage forms, among the Chinese patent medicines approved by CFDA, the top three capsules, tablets and pills appeared the phenomenon of "white heat", accounting for 20.1%, 16.4% and 14.9% respectively, more than half of the total Most of the remaining varieties and dosage forms are scattered, and there are more opportunities in the market The distribution of the dosage forms of Chinese patent medicine approved for production in China, then, what is the focus of the development of Chinese patent medicine market? Market expansion is a general trend in the past two years There are 75 clinical studies of Chinese patent medicines accepted by the drug evaluation center (CDE) of the State Food and drug administration The annual declaration trend is stable, and it is expected that the market of Chinese patent medicine will continue to grow in the next few years Note: rolling year, the 8 full season, a new class of new drugs has made brilliant achievements Among the Chinese patent medicines accepted by CDE, 56 new drugs, including AINING emulsion injection and Bailong liquor, are the most eye-catching In the climate of accelerating the internationalization of traditional Chinese medicine, high-quality innovative drugs must be at the forefront List of Chinese patent medicines (class I new drugs) accepted by CDE data source: CPM database of China Pharmaceutical Industry Information Center